Review backs memantine

April 2006
Pulse;4/20/2006, Vol. 66 Issue 16, p6
The article discusses a research by Rupert McShane and colleagues, which showed the clinical efficacy of memantine in the treatment of moderate to severe Alzheimer's disease. It suggests that memantine should only be used as part of a clinical study. Memantine might also help prevent agitation in these patients.


Related Articles

  • Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer's Disease. Fran çois, Clément; Sintonen, Harri; Sulkava, Raimo; Rive, Benoît // Clinical Drug Investigation;2004, Vol. 24 Issue 7, p373 

    Background: In patients with moderately severe to severe Alzheimer's disease, the N-methyl-D-aspartate (NMDA) antagonist memantine has been shown to improve outcomes and to be associated with reductions in resource utilisation and total healthcare costs relative to no pharmacological...

  • Doctors seek lost data on Alzheimer's vaccine. Abbott, Alison // Nature;8/12/2004, Vol. 430 Issue 7001, p715 

    Reports that researchers who were involved in clinical trials with the first experimental vaccine for Alzheimer's disease are seeking data that were lost because patients who were immunized are no longer being monitored. Reason why trials of the vaccine were abandoned in January 2002; Elan's...

  • Neuroscience 2007.  // BioWorld Today;11/6/2007, Vol. 18 Issue 216, p6 

    The article reports on the preliminary results of a clinical trial conducted by Pipex Pharmaceuticals Inc. based in Ann Arbor, Michigan using its lead anti-copper drug candidate, oral Coprexa in the most commonly utilized transgenic preclinical murine model of Alzheimer's disease. Research data...

  • Axonyx initiates second phase III Alzheimer's disease trial.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p6 

    Axonyx has confirmed the initiation of its second phase Ill international clinical trial with its Alzheimer's disease drug, Phenserine. This second phase Ill trial will recruit patients to randomly receive Phenserine 10mg twice daily, Phenserine 15mg twice daily or placebo. The company intends...

  • Neurochem launches North American phase III clinical trial of Alzhemed.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p6 

    Neurochem Inc. has launched its North American phase Ill clinical trial on Alzhemed, following an investigators' meeting attended by more than 200 clinicians and clinical monitors held in Montreal. The multi-center, randomized, double-blind, placebo-controlled and parallel design North American...

  • Prana: Alzheimer drug shows promise.  // PharmaWatch: CNS;February 2004, Vol. 3 Issue 2, p3 

    Reports on the clinical trial of PBT-1, Prana Biotechnology Ltd.'s Alzheimer's disease drug in Australia. Use of the novel drug to treat Alzheimer's patients whose treatments are limited by symptomatic effect only; Assessment on the safety and efficacy of PBT-1; Advantages of using the novel...

  • CNS News Round-up.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p19 

    The article presents news briefs related to pharmaceutical companies working in the field of central nervous system disorders. Noven has been dealt a worse blow, having received an outright rejection for its application to produce a generic version of Johnson & Johnson's Duragesic pain patch....

  • Prevention Study Halted Amid Concerns About Celebrex.  // JNCI: Journal of the National Cancer Institute;1/19/2005, Vol. 97 Issue 2, p91 

    Reports on the clinical trial of the cyclooxegenase-2 inhibitor drug celecoxib in the U.S. Reasons behind the decision of the trial's data safety and monitoring board to suspend the study; Indications showing colorectal cancer patients taking the drug to have increased risk of major...

  • Epix announces revised results of Phase IIa Alzheimer's trial.  // PharmaWatch: Biotechnology;Mar2008, Vol. 7 Issue 3, p8 

    The article focuses on the revised results of Phase IIa clinical trial of PRX-03140 in Alzheimer's disease treatment conducted by Epix Pharmaceuticals Inc. The trial is designed to assess the effects of the drug as monotherapy and in combination with donepezil. Results show that patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics